Comparative Pharmacology
Head-to-head clinical analysis: PHOTREXA VISCOUS IN DEXTRAN 20 versus PHOTREXA VISCOUS IN DEXTRAN 20 PHOTREXA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHOTREXA VISCOUS IN DEXTRAN 20 versus PHOTREXA VISCOUS IN DEXTRAN 20 PHOTREXA.
PHOTREXA VISCOUS IN DEXTRAN 20% vs PHOTREXA VISCOUS IN DEXTRAN 20%/PHOTREXA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Photosensitizer activation by light to produce reactive oxygen species, causing endothelial damage in choroidal neovascularization.
Photosensitizing agent that is activated by ultraviolet A (UVA) light; causes cross-linking of DNA in rapidly dividing cells, leading to cell death.
Photrexa Viscous (riboflavin 5'-phosphate) in Dextran 20% is administered topically to the cornea after epithelial removal, 1 drop every 2 minutes for 30 minutes (total 15 drops) prior to UV-A irradiation, then continued during irradiation per protocol.
Not applicable. Photrexa Viscous (riboflavin 5'-phosphate in 20% dextran) is used as a photosensitizer during corneal collagen cross-linking (CXL) for keratoconus. The corneal epithelium is removed, and the solution is applied topically to the cornea every 2 minutes for 30 minutes, followed by UV-A irradiation (365 nm, 3 mW/cm²) for 30 minutes.
None Documented
None Documented
Terminal half-life approximately 15–20 minutes; rapid clearance due to renal elimination and tissue binding.
Terminal elimination half-life is approximately 12 hours, supporting once-daily dosing for photosensitization.
Primarily renal excretion as intact drug; <5% metabolized; 90% excreted unchanged in urine within 24 hours.
Primarily excreted via the reticuloendothelial system into the biliary tract and eliminated in feces; less than 1% excreted renally as unchanged drug.
Category C
Category C
Photosensitizer (Dermatologic)
Photosensitizer (Dermatologic)